The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Ab Initio Biotherapeutics; Forty Seven
Leadership - Ab Initio Biotherapeutics
Stock and Other Ownership Interests - Ab Initio Biotherapeutics; Forty Seven
Consulting or Advisory Role - Ligand
Patents, Royalties, Other Intellectual Property - Patent US10316094B2, owned by Stanford University and licensed to Forty Seven, Inc.; Patent US9562087B2, owned by Stanford University and licensed to Ab Initio Biotherapeutics, Inc. (now owned by Ligand Pharmaceuticals); Patent US9845345B2, owned by Ab Initio Biotherapeutics, Inc. (now Ligand Pharmaceuticals).
Travel, Accommodations, Expenses - Forty Seven
Pharmacokinetic (PK)-pharamcodynamic (PD) analysis and receptor occupancy data to support every other week maintenance dosing of magrolimab in combination with azacitidine in MDS/AML patients.
 
Balaji Agoram
Employment - Forty Seven
Stock and Other Ownership Interests - AstraZeneca/MedImmune; Forty Seven
 
ChaoYu Jin
Employment - Forty Seven
Stock and Other Ownership Interests - AstraZeneca; Forty Seven; Roche
Patents, Royalties, Other Intellectual Property - AstraZeneca
 
Roy Maute
No Relationships to Disclose
 
Chris H.M. Takimoto
Employment - Forty Seven
Leadership - Forty Seven
Stock and Other Ownership Interests - Forty Seven; Johnson & Johnson
Consulting or Advisory Role - Biomotiv
Patents, Royalties, Other Intellectual Property - Patent Proposals filed relating to using anti-CD47 antibodies as cancer therapy at my current company of employment, Forty Seven, Inc.
Travel, Accommodations, Expenses - Forty Seven
 
Mark Chao
Employment - Forty Seven
Leadership - Forty Seven
Stock and Other Ownership Interests - Forty Seven; Hepatx
Honoraria - D2G Oncology
Consulting or Advisory Role - Chimera Bioengineering
Patents, Royalties, Other Intellectual Property - I am an inventor on several patents from Stanford University that have been licensed to Forty Seven, Inc. I am also an inventor on patents generated from Forty Seven, Inc.
Travel, Accommodations, Expenses - Forty Seven
 
David Andrew Sallman
Consulting or Advisory Role - Agios; argenx; Celyad
Speakers' Bureau - Abbvie; Agios; Celgene; Incyte; Novartis
Research Funding - Celgene
Patents, Royalties, Other Intellectual Property - Intellectual Property Patent for LB-100 in MDS